CD274 and esophageal squamous cell carcinoma: FDA approval of Tevimbra (tislelizumab-jsgr) in 2025 for first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma (ESCC) marks a milestone, offering PD-1 inhibition with chemotherapy for PD-L1-positive tumors.